On September 16, under the guidance of the Department of Commerce of Guangdong Province, the "2020 China (Guangdong) - U.S. Investment Cooperation Conference-Sminar on Life and Health Industry", co-sponsored by the Commerce Bureau of Shenzhen Municipality, the Municipal Development and Reform Commission and Pingshan District Government, was held in Guangzhou. Rong Peichan, the Second Inspector of the Department of Commerce of Guangdong Province, Chi Weiguo, Deputy Director of Commerce Bureau of Shenzhen Municipality, Li Yong, Director of Pingshan District and other government officials attended the event and delivered speeches. Also, more than 70 representatives from international and domestic enterprises and institutes, including Thermo Fisher from the U.S., Danaher, Pfizer Upjohn, AstraZeneca, China Medical Pharmaceutical Material Association, Institute of Life Science and Pharmaceuticals of Southern University of Science and Technology , Guangzhou Improve Medical, Shenzhen Salubris Pharmaceuticals, participated the meeting.
Rong Peichan, the Second Inspector of the Department of Commerce of Guangdong Province, pointed out that the life and health industry is a strategic emerging industry, with a market valuation of more than ten trillion yuan, planned and developed by the state during the "13th Five-Year Plan" period and is also one of the seven strategic emerging industries that Guangdong Province and Shenzhen Municipality have introduced in. At the end of March this year, Guangdong Province proposed to build a highland for the development of the Guangzhou-Shenzhen bio-pharmaceutical industry, drawing a bright blueprint for the future development of Guangdong's pharmaceutical and health industry. The Department of Commerce of Guangdong Province has organized a series of activities such as Online Investment Conference for Pharmaceutical and Health Industry and the Online Matchmaking Meeting for Biomedical Industry, to publicize Guangdong's policies and measures on biomedical innovation and development so as to attract high-end biopharmaceutical companies from home and abroad and facilitate key enterprises to invest and develop in Guangdong. Shenzhen has already developed a number of pharmaceutical and health industrial clusters such as Shenzhen (Pingshan) National Biological Industry Base , supporting the rapid growth of the relevant industries, including biopharmaceuticals, high-end medical equipment and health services.
Chi Weiguo, the Deputy Director of the Commerce Bureau of Shenzhen Municipality, said that Shenzhen Special Economic Zone, over the last 40 years since its establishment, has become the land of innovation and entrepreneurship, which has cultivated many large and well-known biological and life and health companies such as Mindray, Lifetech, BGI, Hepalink, Hybio Pharmaceutical, China Resources Sanjiu. Shenzhen has also supported many biological and life and health companies to go public. In the first half of this year, confronting the daunting challenges brought by the COVID-19 pandemic and the complex environment at home and abroad, Shenzhen has been working on economic and social development while remaining its efforts in the containment of pandemic. Recovery in manufacturing and commercial sectors has been accelerated, which creates a favorable environment to boost the economy. In the first half of this year, the major economic indicators in Shenzhen continued to improve and the economic performance was picking up. The regional GDP achieved a positive growth with an increase of 0.1% year-on-year; in the first half of this year, more than 150,000 new commercial entities have registered in Shenzhen, up 14.9% year-on-year, injecting new vitality into economic and social development. Shenzhen, once again, stands at a brand new starting point after 40 years of reform and opening up, in the face of the historical opportunities brought by the development of Guangdong-Hong Kong-Macao Greater Bay Area and the Pilot Demonstration Area of Socialism with Chinese Characteristics. We welcome all global investors, especially those in the life and health sector, to invest in Shenzhen and enjoy the benefits of the development.
Li Yong, the Director of Pingshan District, said that Pingshan District is the core area of the National Biological Industry Base, which is the only of its kind in Shenzhen and one of the first batch of programs in the country. The biopharmaceutical industry has grown to be one of the three pillar industries in the District. In the face of the opportunity brought by the development of the core area of Shenzhen National High-tech Zone, Pingshan District will be built as a main park for the biopharmaceutical clusters by taking the Shenzhen National Biological Industry Base as the core platform, so that the biopharmaceutical industry will enjoy a high-quality growth. After more than ten years of development, there are currently more than 600 biomedical companies in the District with the output growth of over 30%, and over 100 new companies are newly established averagely each year. In this way, a biopharmaceutical industry cluster with complete upstream and downstream, distinctive features and significant cluster effects has been initially created.
During the meeting, the Municipal Development and Reform Commission and the Pingshan District Investment Promotion and Service Bureau analyzed and explained on the policies for the biopharmaceutical industry in Shenzhen and details of the Shenzhen National Biological Industry Base.
It is known that Shenzhen Municipal Government has issued the "1+3" documents for the biopharmaceutical industry, focusing on breakthroughs in key generic technologies in the four fields: biopharmaceuticals, medical equipment, BT+IT technology and bioengineering. Pingshan District would be supported to build a main park for the biopharmaceutical clusters. At the same time, Futian District, Guangming District, Longgang District and Dapeng New District would be coordinated to create synergies in innovation and develop in a complementary way, so as to form a new landscape of "One Core and Multiple Centers". It is also important to accelerate the development of the core engine for the biopharmaceutical industry in the Guangdong-Hong Kong-Macao Greater Bay Area, of the demonstration city for the national bioeconomy, and of the renowned biotechnology innovation center and biopharmaceutical cluster in the world.
Pingshan District, the core area of the National Biological Industry Base, which is one of the first batch in the country and the only of its kind in Shenzhen, has brought in Sanofi Pasteur, Chipscreen, Sinopharm Zhijun, Salubris, Edan Instruments and other key enterprises in the industry. The construction of Shenzhen Bay Laboratory R&D and Technology Transfer Center, Pingshan Institute of Biopharmaceuticals of Southern University of Science and Technology, School of Pharmacy of Shenzhen Technology University, Guangdong Medical Devices Quality Surveillance and Test Institute and other scientific research and basic platforms have been included in the planning. Sanofi Pasteur has decided to establish the first international vaccine innovation center in Pingshan.
In addition, experts from home and abroad had a discussion on the global development of health industry against the COVID-19. Dr. Zhang Xumu, the national specially-appointed expert and the Dean of the Institute of Biopharmaceuticals , Southern University of Science and Technology, gave a keynote speech on the development of Shenzhen's life and health industry against the COVID-19, introducing the research and development projects and development prospects of the anti-COVID-19 drugs. Many celebrities carried out a round-table discussion, including Dr. Cheng Zengjiang, the Chairman of PharmaSea (Beijing) and the Founder of Tongxieyi Club, Dr. Zhang Dan, the national specially-appointed expert and the Chairman of Fountain Medical Development, Dr. Li Shengfeng, the national specially-appointed expert and the CEO and Founder of Bio-thera, Dr. Yang Dajun, the CEO and Chairman of Ascentage Pharma, and Ms. Yu Lihua, the General Manager of Greater China, Cytiva (a company under Danaher). Themed by "The Development of Global Life and Health Industry Under COVID-19 Pandemic", the round-table discussion centered on the future trends in the post-pandemic period, challenges brought by the spread of the COVID-19 to the biopharmaceutical and health industry, contributions made by the biopharmaceutical technologies in the containment efforts and the directions of future cooperation in the sector of life and health. According to the round-table discussion, the health industry has been thriving with the growing economy. Therefore, the health industry, which could be characterized by high technology, high quality, high performance and high returns, has the strongest growth potential. According to statistics, in 2020, the scale of the health industry in China is expected to exceed 8 trillion yuan, and in the next 30 years, a huge Blue Ocean Market of more than 16 trillion yuan will be formed.